Milestones of cardiovascular therapy. IV. Reserpine;Milníky kardiovaskulární terapie IV. Reserpin

Casopis Lekaru Ceskych

Volumn 146, Issue 7, 2007, Pages 573-577

  Jerie, P ^a  

^a Švýcarsko ^*  (Switzerland)

Author keywords

Antihypertensives; Brinerdin; Crystepin; Rauwolfia serpentina; Reserpine

Indexed keywords

ANTIHYPERTENSIVE AGENT; RESERPINE;

ARTICLE; HISTORY; HUMAN; HYPERTENSION; MEDICINAL PLANT; MENTAL DISEASE; PHYTOTHERAPY; RAUWOLFIA;

ANTIHYPERTENSIVE AGENTS; HISTORY, 18TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; HYPERTENSION; MENTAL DISORDERS; PHYTOTHERAPY; PLANTS, MEDICINAL; RAUWOLFIA; RESERPINE;

EID: 34547154262     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Ménard, J.: Comment faire progresser la thérapeutique antihypertensive. In: Milliez, P.: Pharmacologie clinique des antihypertenseurs. Paris, Sandoz Editions, 1973, s. 19-35.
2. Widimský, J.: 50 let historie léčby hypertenze. Praha, Triton, 2001, s. 189.
3. Woodson, R. E. Jr., Youngken, H. W., Schlittier, E., Schneider, J. A.: Rauwolfia, Botany, Pharmacognosy, chemistry and pharmacology. Boston, Toronto, Little, Brown and Comp., 1957, s. 145.
4. USPDI 1997 - Drug Information for the Health Care Professional, 17. Ed Rockville, USA, 1997, s. 3362.
5. Kreigová, M. B.: Zelená medicína. Praha, Orbis, 1970, s. 251.
6. Vakil, R. J.: A clinical trial of rauwolfia serpentina in essential hypertension. Brit. Heart. J., 1949, 11, s. 350-358.
7. Wilkins, R. W.: New drug therapies in arterial hypertension. Ann. Intern. Med., 1952, 37, s. 1144-1151.
8. Schlittler, E.: The chemistry of rauwolfia alkaloids. In: Woodson, R. E. et al. s. 50-108 (viz sub 3).
9. Anonymus: The story of Serpasil. CIBA Pharmaceut. Products Inc. New York, Summit, 1955.
10. Gilman, A. G., Goodman, L. S. (eds.): The Pharmacological Basis of Therapeutics, 7th edition. New York, Macmillan, 1985, s. 1839.
11. Švec, F.: Farmakodynamika - II. vyd. Bratislava, Slov. akademie vied, 1956, s. 705.
12. Brod, J.: The Kidney. London, Butterworths, 1973, s. 740.
13. Novartis Index 2000/2001. Basic prescribing information and Basic Succint statements. Basel, Novartis, 2001, s. 876.
14. Vondráček, V., Riedl, O.: Klinická toxikologie. Praha, SZN, 1958, s. 690.
15. Martindale, 2005. The complete drug reference. London, Chicago, Ed S. C. Sweetman, Pharmaceutical Press, 2005, s. 2756.
16. Boston Collaborative Drug Surveillance Program: Reserpine and breast cancer. Lancet, 1974, 2 (7882), s. 669.
17. McMahon, F. G.: Management of essential hypertension. New York, Futura Publ. Copany, Inc., Mount Kisco, 1978, s. 468.
18. Brod, J., Hejl, Z.: Hemodynamické změny při hypotensním působení vútažů z Rauwolfia serpentina. Čas. Lék. čes., 1957, 96, s. 1129.